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Abstract: Background: Hospitalization-associated acute kidney injury (AKI), affecting one-in-five
inpatients, is associated with increased mortality and major adverse cardiac/kidney endpoints. Early
AKI risk stratification may enable closer monitoring and prevention. Given the complexity and
resource utilization of existing machine learning models, we aimed to develop a simpler prediction
model. Methods: Models were trained and validated to predict risk of AKI using electronic health
record (EHR) data available at 24 h of inpatient admission. Input variables included demographics,
laboratory values, medications, and comorbidities. Missing values were imputed using multiple
imputation by chained equations. Results: 26,410 of 209,300 (12.6%) inpatients developed AKI
during admission between 13 July 2012 and 11 July 2018. The area under the receiver operating
characteristic curve (AUROC) was 0.86 for Random Forest and 0.85 for LASSO. Based on Youden’s
Index, a probability cutoff of >0.15 provided sensitivity and specificity of 0.80 and 0.79, respectively.
AKI risk could be successfully predicted in 91% patients who required dialysis. The model predicted
AKI an average of 2.3 days before it developed. Conclusions: The proposed simpler machine learning
model utilizing data available at 24 h of admission is promising for early AKI risk stratification. It
requires external validation and evaluation of effects of risk prediction on clinician behavior and
patient outcomes.
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1. Introduction

with regard to jurisdictional claims in

Acute Kidney Injury (AKI) is a complex pathophysiological entity with various causes
culminating in a sudden decrease in kidney function. Reported in up to one in five
hospitalized patients, the occurrence of AKI has widespread adverse effects on clinical
outcomes as well as economic costs [1]. In a worldwide meta-analysis representing close to
50 million patients, the pooled incidence rate of AKI was even higher in North America:
close to 25%. Patients with AKI were at almost five times the risk of death compared
to patients without AKI. This risk increases with increasing severity of AKI, going up to
25-fold among AKI patients requiring dialysis [2]. AKI has also been associated with an
average of 3.5 days longer hospital lengths of stay and an additional $7500 in healthcare
expenditure per patient [3]. Survivors of AKI continue to struggle with increased risks
of residual disability, non-recovery of kidney function, worsening chronic kidney disease
(CKD) and development of end-stage kidney disease (ESKD) [1].
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The Kidney Disease Improving Global Outcomes (KDIGO) AKI workgroup clinical
practice guidelines identified standard ways of defining AKI and recommended further
research and evaluation of methods to predict risk of developing AKI [4]. Early AKI
prediction and risk stratification holds promise to improve several steps in care: preventive
interventions, closer monitoring, early diagnosis and institution of bundled interventions
and/or clinical decision support systems [5]. Several predictive models have attempted
early AKI risk stratification in hospitalized patients. Unfortunately, many have used
non-standardized AKI definitions, suboptimal methodology, or were specific to particular
sub-populations, hence limiting their utility [6].
More recently, advances in clinical informatics and availability of electronic health
data have led to development of predictive algorithms utilizing artificial intelligence and
machine learning. A key characteristic of these algorithms is the ability to incorporate
multiple data-points from electronic health records (EHR) into AKI risk stratification [7].
Most of these models utilize supervised machine learning classification models, with
some utilizing deep learning and recurrent neural networks. Many of these models use
continuous data input to run ongoing predictions to improve performance [8]. More
complex algorithms add to computational resource use, costs of implementation, and limit
the clinical application of prediction models. Higher number of variables and disparate data
use also predisposes prediction models to issues such as overfitting and hyperparameters,
further limiting usability and generalization [8,9].
While existing AKI prediction models offer good predictive capabilities, they utilize
several dozen variables to make an AKI prediction. When applying these models for
practical use in EHR, there remain concerns that data input disruption or fluctuation in data
quality in any one of the variables can disrupt the entire model output. For instance, authors
from the Yale School of Medicine have described a significant disruption in an AKI alert
system simply because the serum creatinine field was renamed in the EHR. Adjusting model
inputs in response to such occurrences warrants simpler model design. Moreover, complex
models yield a relatively high proportion of false positive predictions [10]. Given these
valid concerns, we aimed to develop a simpler AKI prediction model. Our objective was
to limit the numbers of variables used to accurately predict AKI by using the 20 strongest
predictors obtained during the first 24 h of hospitalization. The 24 h window was chosen
to reduce the computational burden required to run the model and informed by prior
successful attempts that were limited in methodology or sub-populations studied [11,12].
2. Materials and Methods
2.1. Setting and Participants
Geisinger Health is an integrated healthcare system providing care to more than
3 million residents in and around central Pennsylvania. The system is comprised of 10 acute
care hospitals, 2 research centers, a medical school, an insurance company, >1700 physician
group practice and >900 advanced practitioners. All inpatient admissions in this system
from 13 July 2012–11 July 2018 who had a serum creatinine measured were included in
this study. Patients with ESKD, kidney transplant, length of stay less than 48 h and AKI at
admission were excluded.
2.2. Definitions of AKI and Baseline Kidney Function
AKI was defined according to changes in serum creatinine as specified in KDIGO
guidelines [4]. To reduce sample contamination by very transient AKI and lab error, patients
were classified as having AKI if rise in creatinine met at least KDIGO stage 1 AKI criteria
for a minimum of 48 h [13]. The baseline creatinine used to adjudicate AKI was determined
using a validated hierarchy, utilizing a lookback period ranging between 14 to 365 days
prior to admission as the first preference. This definition was chosen in view of a wealth of
AKI phenotyping literature since the KDIGO guidelines were released [14]. This hierarchy
is represented in Table 1.
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Table 1. Descending hierarchy to determine baseline creatinine. Rules in order of preference, 1
through 5.
Rule
1
2
3

4
5

Creatinine Available Prior to Admission
3 or more outpatient values available in
14–365 days prior to admission (PTA)
2 outpatient values available in 14–365 days
PTA + some prior inpatient values
1 or fewer outpatient creatinine values in
14–365 days PTA but outpatient values
available within 18 months PTA
No outpatient creatinine values in 18 months
PTA but patient had prior inpatient
admissions
No prior inpatient or outpatient creatinine
available

Baseline Creatinine
Mean of all outpatient values
Mean of 2 outpatient and
lowest inpatient value
Mean of all outpatient values
Mean of 3 lowest inpatient
values
Creatinine at admission

2.3. Predictors
Predictors and Missing Data
To identify relevant candidate predictors, the full texts of 53 previously published
hospitalization-associated AKI prediction models in various sub-populations were reviewed by at least 2 authors (at least one of the two had to be a nephrologist). A list
of 746 candidate variables studied in these models was compiled [6]. These lists were
presented and reviewed during our research group meetings to establish consensus on
variables of interest. Any variables appearing in more than one predictive model previously were considered. Clinicians also suggested a few new variables of interest (example:
antidiabetic medications, steroid use).
Variables measuring similar parameters but named differently were grouped together (example: essential hypertension, history of hypertension, high blood pressure,
BP > 140/90, systolic hypertension, and diastolic hypertension were all grouped under
hypertension). With the help of clinical pharmacists, relevant medications were grouped together into groups of interest using the American Hospital Formulary Service PharmacologicTherapeutic Classification System. Examples of medication groups of interest include
angiotensin-converting-enzyme inhibitors/angiotensin receptor blockers (ACE/ARB), anticoagulants, antiplatelet agents, nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, etc. At the end of this curation process, 121 variables were tested for inclusion
into the model. A list of the variables tested is available in the Supplemental Table S1.
Variables of interest were then collected from EHR data including demographics,
comorbid conditions, medication use, vital signs, surgical details (if pertinent) and laboratory values taken within the first 24 h of admission. Estimated glomerular filtration rate
(eGFR) was calculated by using the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation [15]. Laboratory values were ranked by total amount of missingness
and split into common measures (whose missing rate was less than 50%) and rare measures
(missing in >50% encounters). Multiple imputation by chained equations (MICE) was
implemented for common variables [16]. Variables with missing rates greater than 85%
after imputation were eliminated from the prediction algorithms.
2.4. Machine Learning Algorithms
Hospitalizations were divided into 2 groups: a training cohort comprised of admissions from 2012 through 2017 and a hold-out cohort comprised of admissions through 2018.
Machine learning algorithms were implemented using variables of interest available in the
first 24 h of admission to predict encounters where the patient developed AKI during the
hospitalization. Predictive algorithms included penalized logistic regression using least
absolute shrinkage and selection operator (LASSO), bootstrap aggregating (random forest)
and boosting (gradient boosting machines). The optimal hyperparameters were selected
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by random search to optimize the model performance from 3-fold cross-validation in the
training cohort.
Logistic regression is a simple and efficient classification algorithm, where each predictor’s importance is explicitly denoted by its corresponding coefficient. LASSO is a L1
penalized regression approach which attempts to avoid overfitting by forcing the coefficients of the least contributive predictors to be exactly zero [17]. Random forest is a machine
learning algorithm that trains a number of decision trees using a combination of bootstrap
aggregating and random feature selection. The hyperparameter set being tuned includes
the number of trees, tree size, and number of features to consider per split in random
forest. Random forest can prevent overfitting by creating random subsets of the features
and training data for each decision tree [18]. Gradient boosting machines is a machine
learning algorithm that converts several weak leaners into a strong learner by correcting
its predecessor’s mistakes in a sequential manner. The hyperparameter set being tuned
includes the number of trees to construct, the maximum depth of each tree and the learning
rate. Early stopping can avoid overfitting by finding the least number of iterations that is
sufficient to build the model and generalizes well to unseen data [19].
2.5. Performance Evaluation and Statistical Analysis
Candidate models were selected based on the result of 3-fold cross validation. The
selected model was retrained using the whole training cohort and evaluated using the
hold-out cohort. Algorithm performance were evaluated in the hold-out cohort using area
under the receiver operating characteristic curve (AUROC) and precision-recall curves for
separability for encounters with and without AKI, and trade-off between precision and
recall for different thresholds, respectively. The probability cut-off point for the AKI prediction outcome was determined based on Youden’s Index to maximize the differentiating
ability when equal weight is given to sensitivity and specificity. Model performance was
then evaluated via 2 by 2 confusion matrix and comparing the sensitivity vs. specificity,
AUROC, and negative predictive value (NPV) based on the confusion matrix. Statistical
analyses were performed using R Statistical Software (RStudio Version 1.0.153).
3. Results
3.1. Baseline Characteristics
After meeting the prespecified inclusion and exclusion criteria, 209,300 unique admissions comprised our final cohort. Out of these, 26,410 (12.6%) had developed AKI
associated with their hospitalization. Table 2 shows the clinical characteristics of those with
and without AKI. Patients who developed AKI were older (70 vs. 63 years; p < 0.001), and
more likely to be male (52% vs. 43%; p < 0.001), and to have a higher body mass index (31.4
vs. 30.5; p < 0.001). Those who developed AKI also had a significantly higher burden of
comorbid conditions like atrial fibrillation (26% vs. 16%), coronary artery disease (34% vs.
22%), cancer (15% vs. 12%), congestive heart failure (CHF) (34% vs. 16%), CKD (38% vs.
17%), obstructive lung disease (21% vs. 17%), diabetes (42% vs. 26%), gastrointestinal bleed
(11% vs. 8%), hypertension (66% vs. 50%), peripheral vascular disease (15% vs. 9 %) and
respiratory failure (14% vs. 9%).
Patients who developed AKI were more likely to be on ACE/ARB (27% vs. 24%),
antianginal medications (32% vs. 21%), anticoagulants (37% vs. 33%), diuretics (55%
vs. 30%), lipid lowering medications (47% vs. 39 %) and nephrotoxic antibiotics (12%
vs. 10%). The AKI group had higher values of blood urea nitrogen (BUN) (40.9 mg/dL
vs. 19.2 mg/dL), serum creatinine (2.1 mg/dL vs. 1.0 mg/dL), and leukocyte count
(11,190/mL vs. 9930/mL), and lower values of serum albumin (3.2 vs. 3.5 g/dL) and
hemoglobin (10.6 vs. 11.5 g/dL). Using prespecified chronological cut-off, 192,720 (92.5%)
admissions were assigned to the training set and 15,555 (7.5%) to the hold-out set, as
shown in Supplemental Figure S1. The percentage of AKI in these datasets (12.5%) and
well as their clinical characteristics, medications and lab values were similar as shown in
Supplemental Table S2.
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Table 2. Characteristics of patients who developed AKI compared to those who did not.
AKI
No AKI
26,345 (12.6)
182,646 (87.4)
70.10 (15.5)
63.25 (19.0)
13,746 (52.2)
79,178 (43.4)
31.38 (8.7)
30.51 (8.3)
Comorbidities
Atrial fibrillation, n (%)
6745 (25.6)
28,225 (15.5)
Coronary artery disease, n (%)
8940 (33.9)
40,102 (22.0)
Cancer, n (%)
3974 (15.1)
22,808 (12.5)
Congestive Heart Failure, n (%)
9048 (34.3)
29,707 (16.3)
Chronic Kidney Disease, n (%)
10,061 (38.2)
31,561 (17.3)
Obstructive Lung Disease, n (%)
5645 (21.4)
31,688 (17.3)
Diabetes Mellitus, n (%)
10,990 (41.7)
47,212 (25.8)
Gastrointestinal Bleed, n (%)
3007 (11.4)
14,666 (8.0)
Hypertension, n (%)
17,303 (65.7)
91,761 (50.2)
Peripheral vascular disease, n (%)
4042 (15.3)
17,206 (9.4)
Respiratory failure, n (%)
3749 (14.2)
16,746 (9.2)
Medications
ACE/ARB, n (%)
7177 (27.2)
44,061 (24.1)
Antianginal medications, n (%)
8470 (32.2)
38,972 (21.3)
Anticoagulants, n (%)
9692 (36.8)
59,381 (32.5)
Diuretics, n (%)
14,345 (54.5)
54,681 (29.9)
Lipid lowering medication, n (%)
12,470 (47.3)
71,550 (39.2)
Nephrotoxic antibiotics, n (%)
3215 (12.2)
18,232 (10.0)
Lab measurements, mean (standard deviation)
Serum albumin, g/dL
3.21 (0.7)
3.54 (0.6)
Total Bilirubin, mg/dL
1.2 (2.7)
0.8 (1.3)
Blood urea nitrogen, mg/dL
40.9 (25.5)
19.2 (12.3)
Serum creatinine, mg/dL
2.1 (1.4)
1.0 (0.5)
Blood glucose, mg/dL
140 (63.3)
131 (53.6)
Hemoglobin, g/dL
10.6 (2.1)
11.5 (2.1)
Prothrombin time, INR
1.8 (1.1)
1.5 (0.8)
Leukocyte count, ×1000/mL
11.2 (10.8)
9.9 (6.6)
Total, n, (%)
Age, mean (SD)
Male gender, n (%)
Body mass index, mean (SD)

p-Value
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

AKI: Acute Kidney Injury, ACE: Angiotensin Converting Enzyme Inhibitor, ARB: Angiotensin Receptor Blocker,
INR: International Normalized Ratio.

3.2. Model Development
In the training dataset, at 24 h of hospitalization, the top 15 predictors for developing
AKI during that hospital stay are shown in Table 3. Many variables overlapped among the
3 different algorithms. The change in serum creatinine during the first 24 h of admission
was the strongest predictor in all the models. Missing percentages for variables before
imputation are shown in Supplemental Table S4. Of note, importance for Random Forest
was defined by purity, the variance in the responses with the addition/subtraction of those
predictors. For LASSO, importance was defined as the absolute value of coefficient of the
corresponding predictor. For GBM, importance was defined based on the improvement
made by each predictor in the split criterion across all the trees that the predictor was used.
The relative importance of predictors is depicted in Supplemental Figure S2.
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Table 3. Top 15 variables in each algorithm.
LASSO
Serum Creatinine **
CKD **
Diuretic use **
Serum albumin
Calcium channel blocker
Vasodilator therapy
Thrombocytopenia **
NSAID use
Steroid use
Antidiabetic meds **
Respiratory failure *
Serum potassium
Nephrotoxic antibiotics *
Cancer
Anticoagulants

Random Forest
Serum Creatinine **
eGFR *
Mean arterial pressure *
CKD **
Diuretic use **
Body Mass Index *
Hypercalcemia *
Hemoglobin *
Platelet count *
White Blood Cell *
Prothrombin time (INR) *
Thrombocytopenia **
Antidiabetic meds **
Hypertension
Congestive Heart Failure

Gradient Boost
Serum Creatinine **
eGFR *
Mean arterial pressure *
CKD **
Diuretic use **
White Blood Cell *
Prothrombin time (INR) *
Serum sodium
Platelet count *
Hemoglobin *
Antidiabetic meds **
Body Mass Index *
Thrombocytopenia **
Hypercalcemia *
Respiratory failure *

* Variable represented in 2 algorithms. ** Variable represented in all 3 algorithms. CKD: Chronic Kidney Disease,
eGFR: Estimated Glomerular Filtration Rate, NSAID: Nonsteroidal Anti-inflammatory Drugs, INR: International
Normalized Ratio

3.3. Model Performance
3.3.1. ROC Curve and Precision-Recall Curve

J. Clin. Med. 2022, 11, 5688

Discrimination performance is for each algorithm using AUROC and average precision
is shown in Figures 1–3. AUROC = 0.85 (95% CI: 0.84–0.86) for LASSO; AUROC = 0.86
(95% CI: 0.85–0.87) for Random Forest, and AUROC = 0.87 (95% CI: 0.86–0.88) for Gradient
Boosting Machines. Average precision indicates Random Forest and Gradient Boosting
Machines can correctly identify the positive HA-AKI without accidentally marking too
many negative as positive (0.55 for LASSO; 0.59 for both Random Forest and Gradient
7 of 12
Boosting Machines). Based on the Brier scores on the validation data (RF: 0.074; GBM: 0.075;
Lasso: 0.076), all algorithms were well-calibrated.
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(b) Precision-Recall (PR) curve. AUC: Area under the curve
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3.3.2. Performance Metrics by Threshold
3.3.2.Varying
Performance
Metrics
Threshold
thresholds
by by
algorithm
showed specificity was closely linked to the thresholds, Varying
while sensitivity
decreased
as thresholds
(Table
4). Youden
Index
was
used
thresholds
by algorithm
showedincreased
specificity
was closely
linked
to the
threshto
select
the optimal
threshold
or cut-off
in predicted
probabilities.
By Youden
varying the
cut-off
olds,
while
sensitivity
decreased
as thresholds
increased
(Table 4).
Index
was
from
list
of
0.05
to
0.95
by
0.05
fixed
interval,
Youden
threshold
indicated
that
the
optimal
used to select the optimal threshold or cut-off in predicted probabilities. By varying the
threshold
felllist
between
andby
0.20
across
3 models.
A cut-off
at 0.15indicated
yielded optimal
cut-off from
of 0.050.15
to 0.95
0.05
fixedthe
interval,
Youden
threshold
that the
balance
sensitivity
and0.15
specificity
foracross
Random
optimalbetween
threshold
fell between
and 0.20
the 3Forest.
models. A cut-off at 0.15 yielded
optimal balance between sensitivity and specificity for Random Forest.
Table 4. Sensitivity, specificity, and NPV by varying cut-off in Lasso, Random Forest and Gradient
Boosting Machines.

Cut-Off
0.05
0.10
0.15
0.20
0.50

Sensitivity
0.96
0.91
0.84
0.76
0.29

Cut-Off

Sensitivity

LASSO
Specificity
0.29
0.51
0.68
0.80
0.98
Random Forest
Specificity

NPV
0.98
0.98
0.97
0.96
0.91
NPV
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Table 4. Sensitivity, specificity, and NPV by varying cut-off in Lasso, Random Forest and Gradient
Boosting Machines.
LASSO
Cut-Off

Sensitivity

Specificity

NPV

0.05
0.10
0.15
0.20
0.50

0.96
0.91
0.84
0.76
0.29

0.29
0.51
0.68
0.80
0.98

0.98
0.98
0.97
0.96
0.91

Random Forest
Cut-Off

Sensitivity

Specificity

NPV

0.05

0.92

0.48

0.98

0.10

0.86

0.69

0.97

0.15

0.80

0.79

0.96

0.20

0.73

0.85

0.96

0.50

0.41

0.97

0.92

Gradient Boosting Machines
Cut-Off

Sensitivity

Specificity

NPV

0.05
0.10
0.15
0.20
0.50

0.90
0.81
0.74
0.67
0.41

0.59
0.77
0.85
0.89
0.97

0.98
0.97
0.96
0.95
0.92

Metrics with cut-off probabilities above 0.50 are not listed as the sensitivity drops to a very low level. NPV:
Negative Predictive Value.

3.3.3. Time from Prediction to AKI and Performance in Dialysis Requiring AKI
The time interval between the model’s AKI prediction and actual occurrence of AKI
was measured as a secondary outcome among the 1550 patients in the validation cohort
where AKI was correctly predicted. Based on the selected Random Forest model with the
Youden threshold of 0.15, the mean number of days from the time of prediction to the date of
AKI were 2.3 with standard deviation of 2.7. The distribution of number of days where the
model could predict AKI before it developed was positively skewed (skewness = 4.09) with
median = 1 and interquartile range 1 to 3. Time between AKI prediction and occurrence
was 1 day in 58.5%, 2 days in 14.9%, 3 days in and 9.1%, 4 days in 5.61%, 5 days in 3.4%
and >5 days in 8.5% of patients who developed AKI.
A sensitivity analysis was also performed for model performance among the 104
patients in the validation cohort who required dialysis. The model correctly predicted AKI
in 95 (90.5%) of those patients.
4. Discussion
Given the high prevalence and incremental costs associated with AKI, there has
been great interest in use of AKI prediction models for early risk stratification. Various
investigators have utilized traditional as well as machine learning prediction algorithms to
achieve this. Unfortunately, widespread application of these models has been limited due
to complex computational needs and variable performance [20,21]. To address limitations
of prior models, we developed and validated a simpler model that can be operationalized
using 15–20 variables obtained during the first 24 h of hospitalization only. Our model
showed excellent prediction for AKI a mean of 2.3 days before it occurs and performed
especially well with the patients who developed AKI requiring dialysis. Our Random
Forest model had the best trade-off between sensitivity and specificity and achieved an
AUROC of 0.86. All our models offered excellent negative predictive value, making it
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possible to stratify patients to lower risk for AKI within 24 h of hospital admission. We
achieved a good balance between sensitivity and specificity for AKI prediction in validation;
both around 80%. We also offer a single prediction model for all hospitalized patients rather
than sub-populations.
Initial work on AKI prediction was limited by use of heterogenous AKI definitions,
non-standardized methodology, and poor performance of traditional models [6]. An early
machine learning predictive model used deep learning and a recurrent neural network to
continuously predict AKI before 24, 48 and 72 h of its occurrence [22]. While they achieved
an AUROC of 0.92 for AKI prediction within 48 h, the amount of data preprocessing
required to integrate more than 600,000 input variables may prove to be prohibitive for
clinical application. Moreover, widespread use would also be limited by the high proportion
of false positive predictions [10]. Several subsequent machine learning AKI prediction
models have been developed. Gameiro et al. reviewed most of these and found that many
were limited to subsets of hospitalized patients like the elderly, cirrhotic, critically ill or
those undergoing cardiac surgery, general surgery or coronary angiography. Hence, these
models are limited in application, requiring use of multiple models and even more intense
computational requirements to cover the entire spectrum of hospitalized patients [7].
On systematic review, eight AKI machine learning models were identified that have
aimed to predict AKI in all medical and surgical admissions, an objective comparable to
ours. While these strived to achieve excellence in AKI prediction, results have been heterogeneous. By design, most machine learning models are developed using retrospective
datasets. Given their recent development, nearly all of them, including ours, lack external
validation [7]. Of these, the model developed by Koyner et al. has been the most promising and subsequently has been externally validated. The continuously running model
initially included 97 variables and was subsequently simplified to 59 variables. Hence, the
computational requirements are expected to be significant if evaluating for widespread
implementation. Moreover, the predictive performance is quite similar to our much simpler
approach that requires fewer resources and only 15–20 variables [23]. The other machine
learning models described showed similar or worse performance compared to our model,
while still utilizing much more data points. In fact, our model’s sensitivity and specificity,
both approaching 80%, is equal to or better than most prior reports. Hence, our study
provides a potential pathway for simplification of AKI machine learning prediction models.
Future studies are required to assess whether this approach can be simplified even further
(fewer or simpler variables?) to reduce the data preprocessing and computational demands
of these models.
Among a few validated prior models, Churpek et al. have developed and externally
validated a gradient boosted machine AKI prediction model for predicting stage 2 AKI
within a 48 h interval. While the model performs well, they excluded any patients with
CKD stage 4 or those who required dialysis within 48 h of admission [23]. Further, while
stage 1 AKI patients have better outcomes compared to stage 2 or 3, they still have much
worse outcomes compared to patients with no AKI [1]. Our model addresses a wider
hospitalized population and all stages of AKI. Prior attempts have been made to simplify
prediction models using our approach: only using data gathered during the first 24 h of
admission. One such group in the UK developed 3 Fuzzy Logic Systems models to identify
any AKI, AKI stage 2/3 or AKI stage 3. Their AKI model, looking at an outcome similar to
ours, had modest performance on internal validation, with AUROC 0.7 [11]. Another such
attempt using the first 24 h of data by a group in the US led to machine AKI prediction
models with only modest performance, an AUROC of 0.660–0.664 [24].
A prospective study of critically ill patients at admission found that machine learning
models offer similar predictive ability as experienced clinicians but with less risk of overestimation [25]. As demonstrated by our model, it is possible to rapidly identify patients at
lower risk for AKI during admission using data obtained during the first 24 h of admission,
with negative predictive value in excess of 95%. Given the widespread prevalence of EHRs
and our significant variables being clinical parameters routinely collected during the first
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24 h of inpatient care, our model may prove to be easier to implement than existing models
utilizing numerous parameters [26]. The standardized definitions of baseline creatinine
also increase the probability that our model would be able to perform well across EHRs
and healthcare systems. This can be contrasted with a recent personalized AKI prediction model where baseline creatinine was defined as values within or immediately prior
to hospitalization. Moreover, that study also excluded even mild CKD patients (serum
creatinine > 1.3 mg/dL), further limiting generalization to all hospitalized patients [27].
Interventions like implementation of guideline-based care bundles targeting patients at
high risk for AKI, as defined by biomarkers, have been shown to reduce the frequency and
severity of AKI after cardiac surgery [28]. Machine learning models like ours may allow
similar risk stratification on broader scale among all hospitalized patients, with the hope of
improving outcomes. One such approach is currently being tested in a National Institutes
of Health–funded clinical trial [29].
Despite the ease of use and other strengths, there are several potential limitations to
our algorithm. While our study used a standardized serum creatinine-based AKI definition
based on KDIGO guidelines, we did not have urine output data available for all patients.
Prior studies have shown that including urine output impacts estimates of prevalence and
outcomes of AKI among hospitalized patients. However, almost all such studies have
been exclusive to critically ill patients. Given that reliable urine output data is seldom
available for the vast majority of hospitalized patients outside intensive care units, this
remains an inherent limitation common in most AKI studies [30]. Our study focused on a
single health system with a relatively homogenous population, and thus external validation
is needed to ensure that our models do not suffer from hyperfit and are generalizable.
It also remains to be seen whether risk stratification based on our model can actually
improve patient outcomes. While a few preventative interventions, like management of
hemodynamics and discontinuation of nephrotoxic medications seem reasonable, there
remains the potential for patient harm by avoidance of clinically indicated contrast studies
and inadequate medication dosing [10]. Prior studies have demonstrated the phenomenon
of “renalism”: denial of medically indicated interventions to patients perceived to be at
high risk for acute kidney injury [31]. This phenomenon will need to measured carefully in
any clinical trials on our approach. Hence, the next logical step after external validation
would be decision curve analyses (to assess impact in practice) and randomized trials of
interventions based on the output of models like ours.
5. Conclusions
We devised and internally validated a machine learning algorithm to accurately predict
AKI 2.3 days before it occurs, using 20 common variables available within the first 24 h of
hospitalization. The model performed well and requires external validation and evaluation
of impact on patient outcomes.
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